Electroporation of Hepatocyte growth factor to the lung induces migration of bone marrow mesenchymal stem cells and reduces lung fibrosis

Gazdhar, Amiq; Fytianos, Kleanthis; Knudsen, Lars; Schliep, Ronja; Müller, Stefan; Geiser, Thomas

doi:10.1183/13993003.congress-2018.pa593

Cited by 1 publication

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…As such, individually designed MSCs may function precisely in the treatment of pulmonary fibrosis. It has been demonstrated that HGF functions as a protective protein in pulmonary fibrosis through binding its receptor, c-met, which is expressed by many types of cells (e.g., epithelial cells, fibroblasts) ( Dohi et al, 2000 ; Watanabe et al, 2005 ; Gazdhar et al, 2007 ; Gazdhar et al, 2013 ; Gazdhar et al, 2018 ). We therefore performed HGF modification in UCMSCs in order to enhance the anti-fibrotic ability of the cells.…”

Section: Discussionmentioning

confidence: 99%

Enhanced secretion of hepatocyte growth factor in human umbilical cord mesenchymal stem cells ameliorates pulmonary fibrosis induced by bleomycin in rats

et al. 2023

View full text Add to dashboard Cite

Umbilical cord mesenchymal stem cells (UCMSCs) are a reportedly promising choice in the treatment of irreversible pulmonary fibrosis and lethal interstitial lung disease with limited drug treatment options. In this study, we investigated the therapeutic efficacy of UCMSCs overexpressing hepatocyte growth factor (HGF), which is considered one of the main anti-fibrotic factors secreted by MSCs. Adenovirus vector carrying the HGF gene was transfected into UCMSCs to produce HGF-modified UCMSCs (HGF-UCMSCs). Transfection promoted the proliferation of UCMSCs and did not change the morphology, and differentiation ability, or biomarkers. Rats were injected with HGF-UCMSCs on days 7 and 11 after intratracheal administration of bleomycin (10 mg/kg). We performed an analysis of histopathology and lung function to evaluate the anti-fibrotic effect. The results showed that HGF-UCMSCs decreased the Ashcroft scores in hematoxylin and eosin-stained sections, the percentage positive area in Masson trichrome-stained sections, and the hydroxyproline level in lungs. Forced expiratory volume in the first 300 m/forced vital capacity was also improved by HGF-UCMSCs. To explore the possible therapeutic mechanism of HGF-UCMSCs, we detected inflammatory factors in the lungs and performed mRNA sequencing in UCMSCs and HGF-UCMSCs. The data indicated that inhibition of interleukin-17 in the lung may be related to the anti-fibrosis of HGF-UCMSCs, and overexpressed HGF probably played a primary role in the treatment. Collectively, our study findings suggested that the overexpression of HGF may improve the anti-fibrotic effect of UCMSCs through directly or indirectly interacting with interleukin-17-producing cells in fibrotic lungs.

show abstract